SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Saxagliptin And Metformin Hydrochloride, and what generic alternatives are available?
Saxagliptin And Metformin Hydrochloride is a drug marketed by Mylan and Sun Pharm and is included in two NDAs.
The generic ingredient in SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Saxagliptin And Metformin Hydrochloride
A generic version of SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE was approved as metformin hydrochloride; saxagliptin hydrochloride by DR REDDYS LABS SA on August 9th, 2023.
Summary for SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 60 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sabyasachi Sen | Phase 4 |
First People's Hospital, Shunde China | Phase 4 |
Zhujiang Hospital | Phase 4 |
See all SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE clinical trials
Pharmacology for SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE
Drug Class | Biguanide Dipeptidyl Peptidase 4 Inhibitor |
Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |